Benzodiazepines, Amphetamines, Testosterone, and Sildenafil as New Candidate Drugs for Sexual Interest, Desire and/or Arousal Disorder

Author(s): Richard J. Wix*, Ezequiel Uribe

Journal Name: Current Psychopharmacology

Volume 10 , Issue 3 , 2021

Become EABM
Become Reviewer
Call for Editor


Background: The FDA-approved drugs for female sexual interest, desire and/or arousal disorder (FSIAD), and hypoactive sexual desire disorder (HSDD); however, these drugs have low tolerability for patients because of their multiple side effects and do not show actual therapeutic efficacy. Hypoactive Sexual Desire affects approximately 750.000.000 to 1.400.000.000 people worldwide.

Methods: In this paper, we analyze therapeutic candidates in clinical practice as well as the methodologies of clinicaltrials of possible therapeutic targets of different systems related to the disorder.

Results: Therefore, clinical trials of new drugs (benzodiazepines, amphetamines, testosterone, sildenafil, or new compound) to evaluate their efficacy in treating this disorder are necessary.

Keywords: Increases, sexual, interest, desire, arousal, new drugs, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 01 March, 2021
Page: [208 - 217]
Pages: 10
DOI: 10.2174/2211556010666210301144022
Price: $95

Article Metrics

PDF: 523